DUK
37
2
AN
47
3
LB
45
15
GLW
48
2
BEN
34
6
AXP
64
4
NUE
51
3
RL
72
3
NOC
45
13
HD
49
5
AVB
54
9
BAC
39
3
STX
53
3
IR
61
6
EMN
49
3
KHC
20
2
MHK
46
3
OI
34
6
VLO
33
3
DD
64
9
DUK
37
2
AN
47
3
LB
45
15
GLW
48
2
BEN
34
6
AXP
64
4
NUE
51
3
RL
72
3
NOC
45
13
HD
49
5
AVB
54
9
BAC
39
3
STX
53
3
IR
61
6
EMN
49
3
KHC
20
2
MHK
46
3
OI
34
6
VLO
33
3
DD
64
9
Financhill
Back

Halozyme Therapeutics Quote, Financials, Valuation and Earnings

Write This Down: Tuesday at 2 p.m. ET!

Don't Miss Our LIVE Trade
Buy
69

HALO
Halozyme Therapeutics

Last Price:
60.65
Seasonality Move:
16.49%

7 Day Trial

ALL ACCESS PASS

$ 7

Yours Free! Top SIX AI Dividend Stocks Right Now

NO CREDIT CARD REQUIRED!

Halozyme Therapeutics Price Quote

$60.65
+1.93 (+3.29%)
(Updated: November 6, 2024 at 4:25 PM ET)

Halozyme Therapeutics Key Stats

Buy
69
Halozyme Therapeutics (HALO) is a Buy
Day range:
$57.09 - $58.74
52-week range:
$33.15 - $65.53
Dividend yield:
0%
P/E ratio:
27.96
P/S ratio:
8.05
P/B ratio:
16.5%
Volume:
1.1M
Avg. volume:
1.4M
1-year change:
65.04%
Market cap:
$7.5B
Revenue:
$829.3M
EPS:
$3.02

How Much Does Halozyme Therapeutics Make?

Is Halozyme Therapeutics Growing As A Company?

  • What Is Halozyme Therapeutics's Growth Rate Quarterly?
    Quarterly YoY revenue growth is 0.34%
  • What Is Halozyme Therapeutics's EPS Quarterly YoY Growth Rate?
    Quarterly, year-over-year diluted EPS growth rate is 0.72%

Halozyme Therapeutics Stock Price Performance

What Is Halozyme Therapeutics 52-Week High & Low?

Halozyme Therapeutics Price To Free Cash Flow

Is It Risky To Buy Halozyme Therapeutics?

Is Halozyme Therapeutics Cash Flow Positive?

  • What Is HALO Cash Flow From Operations?
    Cash flow from operations (TTM) is $403M
  • What Is Halozyme Therapeutics’s Cash Flow From Financing?
    Cash flow from financing (TTM) is -$222.4M
  • What Is Halozyme Therapeutics’s Cash Flow From Investing?
    Cash flow from investing (TTM) is -$300.5M

Halozyme Therapeutics Return On Invested Capital

  • Is Management Doing A Good Job?
    HALO return on invested capital is 22.41%
  • What Is Halozyme Therapeutics Return On Assets?
    ROA measures how assets are converting to revenues and is 20.54%
  • What Is HALO Return On Equity?
    ROE is a measure of profitability and is 156.62%

Halozyme Therapeutics Earnings Date & Stock Price

Halozyme Therapeutics Competitors

Halozyme Therapeutics Dividend Yield

Halozyme Therapeutics Analyst Estimates

YoY Growth Past Surprise
EPS: 72.13% 27.05%
Revenue: 34.28% 15.04%

Analyst Recommendations

Buy Recommendations: 3
Hold Recommendations: 5
Sell Recommendations: 0
Price Target: 62.60
Upside from Last Price: 6.61%

Major Shareholders

  • How many HALO shares are owned by institutional investors?
    204.5M HALO shares are owned by institutional investors
  • How many HALO shares are owned by insiders?
    11.5M HALO shares are owned by insiders